Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis.

ABSTRACT:

Background

Predicting disease progression in multiple sclerosis (MS) remains challenging. PET imaging with 18 kDa translocator protein (TSPO) radioligands can detect microglial and astrocyte activation beyond MRI-visible lesions, which has been shown to be highly predictive of disease progression. We previously demonstrated that nuclear magnetic resonance (NMR)-based metabolomics could accurately distinguish between relapsing-remitting (RRMS) and secondary progressive MS (SPMS). This study investigates whether combining TSPO imaging with metabolomics enhances predictive accuracy in a similar setting.

Methods

Blood samples were collected from 87 MS patients undergoing PET imaging with the TSPO-binding radioligand ¹¹C-PK11195 in Finland. Patient disability was asses

SUBMITTER: Radford-Smith DE 

PROVIDER: S-EPMC12004482 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature